NRIX Nurix Therapeutics, Inc.
Q3 2025 10-Q
Nurix Therapeutics, Inc. (NRIX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 9, 2025 for the fiscal period ending Aug 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • No newly added risk factors explicitly identified; financial risks updated with net loss $186.2M for nine months ended August 31, 2025 vs prior year
- • Most materially updated risk: cash and equivalents $428.8M as of August 31, 2025, sufficient for next 12 months but additional funding needs uncertain
Quarterly Financial SummaryXBRL
Revenue
$8M
▼ -37.3% YoY▼ -82.1% QoQ
Net Income
-$86M
▼ -76.5% YoY▼ -98.8% QoQ
Operating Margin
-1157.7%
▼ -72382bp YoY▼ -104797bp QoQ
Net Margin
-1094.8%
▼ -70586bp YoY▼ -99611bp QoQ
ROE
-23.2%
Total Assets
$522M
EPS (Diluted)
$-1.03
▼ -56.1% YoY▼ -98.1% QoQ
Operating Cash Flow
-$57M
▼ -36.1% YoY▲ +9.1% QoQ
Source: XBRL data from Nurix Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Nurix Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.